{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024352","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.945125+00:00","generated_at":"2026-05-15T18:48:43.544143+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital","bullets":["Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.","About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.","SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.","Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.","Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024352","json":"https://secwatch.observer/filing/0001213900-26-024352.json","markdown":"https://secwatch.observer/filing/0001213900-26-024352.md","text":"https://secwatch.observer/filing/0001213900-26-024352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/0001213900-26-024352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/ea0280257-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:48:43.544143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d9c32140cc61cece61acee33a5a35cb1cf9728d","claim":"Bluejay Diagnostics, Inc. reported the fiscal year ended December 31, 2025 results: net income net losses of approximately $6.8 million.","evidence_excerpt":"The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/0001213900-26-024352-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Net income","value":"net losses of approximately $6.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}